GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » POINT Biopharma Global Inc (NAS:PNT) » Definitions » Gross Margin %

POINT Biopharma Global (POINT Biopharma Global) Gross Margin % : 0.00% (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is POINT Biopharma Global Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. POINT Biopharma Global's Gross Profit for the three months ended in Sep. 2023 was $2.8 Mil. POINT Biopharma Global's Revenue for the three months ended in Sep. 2023 was $2.8 Mil. Therefore, POINT Biopharma Global's Gross Margin % for the quarter that ended in Sep. 2023 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for POINT Biopharma Global's Gross Margin % or its related term are showing as below:


PNT's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.53
* Ranked among companies with meaningful Gross Margin % only.

POINT Biopharma Global had a gross margin of N/A% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for POINT Biopharma Global was 0.00% per year.


POINT Biopharma Global Gross Margin % Historical Data

The historical data trend for POINT Biopharma Global's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

POINT Biopharma Global Gross Margin % Chart

POINT Biopharma Global Annual Data
Trend Dec20 Dec21 Dec22
Gross Margin %
- - -

POINT Biopharma Global Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of POINT Biopharma Global's Gross Margin %

For the Biotechnology subindustry, POINT Biopharma Global's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


POINT Biopharma Global's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, POINT Biopharma Global's Gross Margin % distribution charts can be found below:

* The bar in red indicates where POINT Biopharma Global's Gross Margin % falls into.



POINT Biopharma Global Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

POINT Biopharma Global's Gross Margin for the fiscal year that ended in Dec. 2022 is calculated as

Gross Margin % (A: Dec. 2022 )=Gross Profit (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=226.6 / 226.58
=(Revenue - Cost of Goods Sold) / Revenue
=(226.58 - 0) / 226.58
=N/A %

POINT Biopharma Global's Gross Margin for the quarter that ended in Sep. 2023 is calculated as


Gross Margin % (Q: Sep. 2023 )=Gross Profit (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=2.8 / 2.79
=(Revenue - Cost of Goods Sold) / Revenue
=(2.79 - 0) / 2.79
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


POINT Biopharma Global  (NAS:PNT) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

POINT Biopharma Global had a gross margin of N/A% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


POINT Biopharma Global Gross Margin % Related Terms

Thank you for viewing the detailed overview of POINT Biopharma Global's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


POINT Biopharma Global (POINT Biopharma Global) Business Description

Traded in Other Exchanges
N/A
Address
4850 West 78th Street, Indianapolis, IN, USA, 46268
POINT Biopharma Global Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Its product pipeline includes PNT2002; PNT2004; PNT2003; PNT2001 and others.
Executives
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bridget A Martell director C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Joe A. Mccann director, officer: Chief Executive Officer 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Rajesh Malik director 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Gerald L. Hogue director 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
David Charles Lubner director C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472